EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1)

Amy Rieborn, Niels A D Guchelaar, Teun van Gelder, Hans Gelderblom, Saskia A C Luelmo, Nikki Kerssemakers, Paul A P Hamberg, Stijn L W Koolen, Ron H J Mathijssen, Dirk Jan A R Moes iD, Tom van der Hulle

Clinical Pharmacokinetics · 2026

DOI: 10.1007/s40262-025-01612-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacokinetics, 2026. Verfasst von Amy Rieborn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Pyridines, Anilides, Breakfast, Food-Drug Interactions. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma. The current patient-unfriendly advice to ingest cabozantinib in a fasted state is based on an increase of 57% in the area under the concentration-time curve after ingestion with a high-fat meal. Taking cabozantinib with a meal that is suitable for daily practice to increase bioavailability could aid in developing alternative dosing strategies. In this study, we aim to investigate the impact of taking cabozantinib with a light breakfast on exposure and toxicity. METHODS: An open-label, randomized, cross-over, pharmacokinetic evaluation study was performed. In the standard regimen, patients took cabozantinib in a fasted state. In the experimental regimen, patients took cabozantinib with a light breakfast. After 4 weeks, pharmacokinetic samples were obtained for area under the concentration-time curve from 0 to 24 h estimation and patients thereafter switched to the other regimen. Patients were monitored for serious adverse events. RESULTS: Twelve patients completed study procedures. The area under the concentration-time curve for taking cabozantinib in a fasted state and with a light breakfast showed a mean difference of + 8.3% (geometric mean ratio, 90% confidence interval 101-117). Similar results were obtained for trough concentration (mean difference 2.5%, geometric mean ratio, 90% confidence interval 90.7-116.0) and maximum concentration (mean difference 14%, geometric mean ratio, 90% confidence interval 103.7-127.6). No differences in serious adverse events were observed. CONCLUSIONS: Taking cabozantinib with a light breakfast leads to a small increase in exposure. Patients for whom taking cabozantinib in a fasted state is unpleasant are now able to take it with a light breakfast, without an increased risk for exposure-related toxicity. CLINICAL TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov under the number NCT05263245.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesAnilidesBreakfastFood-Drug InteractionsProtein Kinase InhibitorsAntineoplastic AgentsHumansCross-Over StudiesMaleFemaleMiddle AgedAgedArea Under CurveAdultFastingBiological Availability

Substanzen

PyridinescabozantinibAnilidesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Department of Pharmacy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. d.j.a.r.moes@lumc.nl.

ORCID-Profile: Dirk Jan A R Moes

Zitieren

APA

Rieborn, A., Guchelaar, N. A. D., van Gelder, T., Gelderblom, H., Luelmo, S. A. C., Kerssemakers, N., Hamberg, P. A. P., Koolen, S. L. W., Mathijssen, R. H. J., Moes, D. J. A. R., & van der Hulle, T. (2026). The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1). Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01612-2

Vancouver

Rieborn A, Guchelaar NAD, van Gelder T, Gelderblom H, Luelmo SAC, Kerssemakers N, et al. The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1). Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-025-01612-2

BibTeX
@article{Rieborn2026,
  author = {Rieborn, Amy and Guchelaar, Niels A D and van Gelder, Teun and Gelderblom, Hans and Luelmo, Saskia A C and Kerssemakers, Nikki and Hamberg, Paul A P and Koolen, Stijn L W and Mathijssen, Ron H J and Moes, Dirk Jan A R and van der Hulle, Tom},
  title = {The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1)},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  doi = {10.1007/s40262-025-01612-2}
}
Kostenlos starten →